Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631330 | 1.00 | BTK (0.37) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL13618997 | 1.00 | BTK (0.37) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL16664797 | 0.91 | BTK (0.36) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL30951784 | 0.91 | BTK (0.37) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL13618991 | 0.90 | MAOB (0.39) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL19783843 | 0.87 | BTK (0.51) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL13618972 | 0.87 | BTK (0.51) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL16668084 | 0.87 | BTK (0.51) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL13748220 | 0.87 | BTK (0.51) | BTKMAOBMAOAKDM1ASYK | |
| SCHEMBL13696102 | 0.84 | BTK (0.37) | BTKMAOBMAOAKDM1ASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2980067-B1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9447118-B2 | Preparation method of optically active diamine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9447118-B2 | Preparation method of optically active diamine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-20 | — | — | US | disclosed |
| EP-2980067-A1 | PROCESSES FOR PREPARING OPTICALLY ACTIVE DIAMINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20150353577-A1 | METHOD FOR PRODUCING (1S,4S,5S)-4-BROMO-6-OXABICYCLO[3.2.1]OCTAN-7-ONE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-10 | — | — | US | disclosed |
| US-9175012-B2 | Method for producing optically active diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-03 | — | — | US | disclosed |
| US-9175012-B2 | Method for producing optically active diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2407450-B1 | Method for producing optically active diamine derivative | DAIICHI SANKYO CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270446-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270446-A1 | DIAMINE DERIVATIVES | F2, TFPI, F3 | BTK 420/4885MAOB 161/4885MAOA 168/4885 |
| US-20150353577-A1 | METHOD FOR PRODUCING (1S,4S,5S)-4-BROMO-6-OXABICYCLO[3.2.1]OCTAN-7-ONE | F7, MAOA, F13A1 | BTK 635/4885MAOB 39/4885MAOA 2/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | BTK 1281/4885MAOB 2147/4885MAOA 3264/4885 |
| US-20160016974-A1 | PREPARATION METHOD OF OPTICALLY ACTIVE DIAMINE COMPOUND | F12, F8, F11 | BTK 2151/4885MAOB 96/4885MAOA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.